CSL Cuts FY26 Guidance by $650M but Eyes $500M Savings to Rebuild Earnings
CSL cuts FY26 guidance as Interim CEO completes 90-day review
In an investor presentation delivered on 11 May 2026, CSL Limited (ASX: CSL) revised its full-year financial guidance downward, with Interim Chief Executive Officer and Managing Director Gordon Naylor and Chief Financial Officer Ken Lim outlining three discrete revenue headwinds totalling approximately $650 million that will weigh on FY26 results. Revised guidance points to revenue of approximately $15.2 billion and NPATA of approximately $3.1 billion, both on a constant currency basis and excluding restructuring and impairment costs.
Management was explicit that the revision does not reflect a deterioration in underlying demand. Rather, the presentation framed the shortfall as a timing issue, with early commercial indicators pointing to a business beginning to regain momentum. A foreign exchange headwind of approximately $20 million is also anticipated if current rates hold for the remainder of FY26.
Gordon Naylor, Interim CEO & Managing Director
“Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise.”
When big ASX news breaks, our subscribers know first
What the 90-day review found and what’s being done about it
Strengths management is building on
Naylor’s 90-day review identified several durable business strengths that underpin management’s confidence in a return to profitable growth:
- Strong culture and people across the organisation
- An established rare diseases franchise with further growth potential
- Demonstrated strengths in plasma collection and influenza vaccines
- Strong cash flow generation and financial capacity
Three action areas driving the turnaround
The presentation identified three strategic action areas, each with a clearly defined challenge and an accelerating response.
| Action Area | Challenge | Response |
|---|---|---|
| Portfolio growth | Historical growth expectations not delivered; several Phase 3 failures; improvement in competitors’ capabilities | Innovation strategy refocusing on life cycle management, novel modalities, and partnering; restructure of R&D, Commercial, Medical Affairs, and Business Development |
| Operating model & supply chain | Slow to respond to rising costs; overly centralised decision-making; organisation became too complex | Transformation initiatives accelerated; increased focus on plasma collections and manufacturing efficiencies; simplification and accountability measures underway |
| Capital allocation | Infrastructure overbuild; CSL Vifor acquisition underperformed expectations; invested capital grew faster than earnings | Capital allocation priorities refocused on reinvestment in growth, leverage of 1.5–2x Net Debt/EBITDA, and return of surplus cash to shareholders |
The transformation programme underpinning these actions carries a target of $500 million to $550 million in annualised savings by FY28, a figure management highlighted as central to the financial recovery thesis.
Breaking down the guidance revision
The three revenue headwinds explained
Each of the three revenue headwinds contributing to the guidance downgrade has a distinct cause, and management was careful to distinguish operational impacts from underlying demand signals.
U.S. Immunoglobulin (approximately $300 million impact)
End-customer demand for immunoglobulin in the United States continues to grow at mid-to-high single digits, in line with CSL’s own expectations. The revenue shortfall is not a demand problem. It reflects CSL’s deliberate normalisation of channel inventory levels, meaning the company is drawing down stock held at the distribution layer rather than supplying new product into a softening market. Market share data supports this reading: PRIVIGEN IVIg share grew from 19% in CY2023 to 21% in CY2025, while HIZENTRA SCIg share moved from 57% to 55% over the same period.
Albumin in China (approximately $200 million impact)
The China albumin market has experienced a decline in market value even as volumes have stabilised. CSL’s share within that market is actually expanding, with more than 100 new hospitals added and hospital market share growing by +0.5%. The revenue impact is therefore a function of price and market value compression, not volume loss or share erosion.
Other (approximately $150 million impact)
A combination of factors makes up the remaining headwind: the ongoing impact of Middle East conflict on certain markets, a revised growth trajectory for HEMGENIX (with approximately 90 patients treated to date), and increased competition in the iron segment under CSL Vifor.
The next major ASX story will hit our subscribers first
Early indicators, impairments, and the road ahead
Signs the strategy is gaining traction
Alongside the guidance revision, the presentation highlighted a range of early commercial data points management cited as evidence that strategic initiatives are beginning to work:
- Immunoglobulin is regaining share based on end-customer demand trends
- ANDEMBRY has been launched in more than 12 markets with approximately 1,200 patients now on treatment, and strong uptake reported
- CSL Seqirus has grown its global seasonal and pandemic influenza market share from 29% in 2020 to 37% in 2025
- More than 100 new hospitals added in China for albumin, with market share continuing to grow
- CSL Seqirus’ FY26 financial performance is expected to be moderately stronger than previously anticipated
The impairment picture
The presentation flagged additional non-cash, pre-tax impairments of approximately $5 billion expected to be recognised across FY26 and FY27, separate from the $1.5 billion already recognised at the 1H FY26 results. These impairments relate to CSL Vifor intangible assets (including the product portfolio) and under-utilised property, plant and equipment.
Management was clear these are non-cash charges and do not affect the operational or liquidity position of the business. All figures remain subject to further analysis, business developments, external audit, and Board approval. The next update will be provided at CSL’s FY26 full-year results, scheduled for 18 August 2026.
Leadership transition
The presentation also confirmed several leadership developments:
- The global CEO search is progressing as planned
- Gordon Naylor is expected to remain on the CSL Board of Directors as a Non-Executive Director following the appointment and transition of the incoming CEO
- Andy Schmeltz is retiring as Chief Commercial Officer for personal reasons
- Diego Sacristan has been appointed as Chief Commercial Officer for CSL Behring and CSL Vifor, effective 1 July 2026, bringing deep industry commercial experience having recently been responsible for CSL Behring’s U.S. business and previously led the company’s international markets
- Steve Marlow, EVP CSL Plasma, has been appointed to the Global Leadership Team
Detailed financial and operational performance for the full year will be presented at the FY26 results announcement on 18 August 2026.
Don’t Miss the Next Healthcare Sector Mover
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done. Join 20,000+ subscribers staying ahead of market-moving announcements. Click the “Free Alerts” button at StockWire X to get the next major healthcare update the moment it breaks.